Research Analysts’ Recent Ratings Updates for Zimmer Biomet (ZBH)

Zimmer Biomet (NYSE: ZBH) has recently received a number of price target changes and ratings updates:

  • 3/23/2018 – Zimmer Biomet was downgraded by analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating.
  • 3/23/2018 – Zimmer Biomet was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 3/15/2018 – Zimmer Biomet is now covered by analysts at Oppenheimer Holdings Inc.. They set an “outperform” rating and a $135.00 price target on the stock.
  • 3/15/2018 – Zimmer Biomet is now covered by analysts at Raymond James Financial. They set an “outperform” rating and a $135.00 price target on the stock.
  • 2/27/2018 – Zimmer Biomet had its price target lowered by analysts at Citigroup from $132.00 to $121.00. They now have a “neutral” rating on the stock.
  • 2/26/2018 – Zimmer Biomet had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an “overweight” rating on the stock.
  • 2/5/2018 – Zimmer Biomet had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $140.00 price target on the stock. They wrote, “ZBH received FDA clearance for its Persona cementless knee, earlier than we expected.””

Shares of ZBH stock opened at $109.04 on Monday. Zimmer Biomet Holdings Inc has a fifty-two week low of $107.32 and a fifty-two week high of $133.49. The firm has a market capitalization of $22,151.15, a PE ratio of 13.58, a PEG ratio of 1.90 and a beta of 1.13. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.50 and a quick ratio of 0.81.

How to Become a New Pot Stock Millionaire

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.10. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The business had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.03 billion. During the same quarter last year, the business posted $2.14 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. sell-side analysts anticipate that Zimmer Biomet Holdings Inc will post 7.8 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend is Wednesday, March 28th. Zimmer Biomet’s dividend payout ratio is currently 11.96%.

In related news, VP Chad F. Phipps sold 20,826 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $115.95, for a total transaction of $2,414,774.70. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Bryan C. Hanson acquired 25,077 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were bought at an average cost of $119.68 per share, for a total transaction of $3,001,215.36. The disclosure for this purchase can be found here. Company insiders own 1.07% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Armor Investment Advisors LLC boosted its stake in shares of Zimmer Biomet by 11.7% during the fourth quarter. Armor Investment Advisors LLC now owns 3,830 shares of the medical equipment provider’s stock valued at $463,000 after acquiring an additional 400 shares during the last quarter. Daiwa SB Investments Ltd. boosted its stake in shares of Zimmer Biomet by 5.2% during the fourth quarter. Daiwa SB Investments Ltd. now owns 8,470 shares of the medical equipment provider’s stock valued at $1,022,000 after acquiring an additional 420 shares during the last quarter. Financial Counselors Inc. boosted its stake in shares of Zimmer Biomet by 5.2% during the fourth quarter. Financial Counselors Inc. now owns 8,709 shares of the medical equipment provider’s stock valued at $1,051,000 after acquiring an additional 431 shares during the last quarter. Creative Planning boosted its stake in shares of Zimmer Biomet by 2.9% during the fourth quarter. Creative Planning now owns 15,765 shares of the medical equipment provider’s stock valued at $1,902,000 after acquiring an additional 443 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC boosted its stake in shares of Zimmer Biomet by 0.9% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 49,118 shares of the medical equipment provider’s stock valued at $5,926,000 after acquiring an additional 447 shares during the last quarter. 86.51% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Receive News & Ratings for Zimmer Biomet Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply